Abbott Laboratories
100 Abbott Park Road
Abbott Park
Illinois
United States
About Abbott Laboratories
1466 articles about Abbott Laboratories
-
Late-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3™ Heart Pump
11/13/2023
Abbott announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3™ heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant.
-
Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV
11/2/2023
Abbott has received U.S. Food and Drug Administration approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays.
-
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
10/31/2023
Stereotaxis announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System.
-
Late-Breaking Data Show Esprit™ BTK Drug-Eluting Resorbable Scaffold Reduces Chronic Limb-Threatening Ischemia Progression Compared to the Standard of Care
10/25/2023
Abbott (NYSE: ABT) today announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK) in people with chronic limb-threatening ischemia (CLTI).
-
Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves
10/24/2023
Abbott (NYSE: ABT) today announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease.
-
Abbott Hosts Conference Call for Third-Quarter 2023 Earnings
9/27/2023
Abbott will announce its third-quarter 2023 financial results on Wednesday, Oct. 18, before the market opens.
-
Abbott Declares 399th Consecutive Quarterly Dividend
9/21/2023
This marks the 399th consecutive quarterly dividend to be paid by Abbott since 1924.
-
Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets
9/20/2023
Abbott (NYSE: ABT) announced today an agreement with Spain-based global biotech leader mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women's health and respiratory diseases in emerging markets.
-
Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes
9/5/2023
Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.
-
Abbott's FreeStyle Libre® 2 Receives National Reimbursement in France for All People with Diabetes Who Use Insulin¹
6/22/2023
Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 system to include all people who use basal insulin as part of their diabetes management.
-
Abbott Declares 398th Consecutive Quarterly Dividend
6/9/2023
The board of directors of Abbott declared a quarterly common dividend of 51 cents per share.
-
Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm
5/19/2023
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's TactiFlex™ Ablation Catheter, Sensor Enabled™, the world's first ablation catheter with a flexible tip and contact force technology.
-
Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
5/19/2023
Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems.
-
Abbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term
5/18/2023
Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
-
AHF: Pharma Companies Scrapping HIV Diagnostics Endangers Patients
5/17/2023
AIDS Healthcare Foundation supports an appeal by Médecins Sans Frontières urging Abbott Laboratories and Becton Dickinson to continue production of equipment and consumables for point-of-care CD4 machines. Both companies have announced that they will phase out the production of cartridges and devices over the coming years, including Abbott’s Pima CD4 analyzers, which AHF widely uses around the world.
-
Abbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options
5/16/2023
Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
-
Abbott's Life Support System Receives New FDA Clearances to Help Doctors Treat More Critically Ill Patients
4/25/2023
Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system.
-
Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries
4/17/2023
More Medicare beneficiaries than ever before who are living with diabetes and use insulin1 will now be eligible for reimbursement when using Abbott's (NYSE: ABT) FreeStyle Libre® portfolio3,4 – the most prescribed and affordable continuous glucose monitoring system (CGM) in the United States.
-
FDA Clears Reader for Abbott's FreeStyle Libre® 3 System
4/14/2023
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world's smallest, thinnest and most discreet5 glucose sensor.
-
Abbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion
3/7/2023
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration clearance for what will be the first commercially available laboratory traumatic brain injury (TBI) blood test, making it widely available to hospitals in the United States.